Bharat Biotech seeks DCGI’s nod to extend shelf life of Covaxin

The Hyderabad-based Bharat Biotech was given permission for sale and distribution of Covaxin with shelf life of six months when stored at two to eight degrees Celsius.

42

Bharat Biotech has written to the India’s drug regulator (DCGI) seeking extension of the shelf-life of its indigenously developed C-19 vaccine Covaxin from six to 24 months, sources said on Sunday.


Also read more articles on Bharat Biotech, click here


Covaxin, along with Covishield manufactured by Serum Institute of India, are the two vaccines so far being used in India’s current C-19 vaccination drive. Russian vaccine Sputnik-V has also been approved for emergency use in India.

DCGI CDSCO

The Hyderabad-based Bharat Biotech was given permission for sale and distribution of Covaxin with shelf life of six months when stored at two to eight degrees Celsius.

“Now, we are herewith applying for the extension of shelf life from six months to 24 months when stored at 2-8 degrees Celsius,” the firm said in its application to the Drugs Controller General of India.

In support of their proposal, Bharat Biotech has submitted updated accelerated and real-time stability data of Covaxin along with the justification for the extension of shelf-life.


Also read:

Govt exempts customs duty on C-19 vaccine, Oxygen and related equipment

Pharma firms ramp up Remdesivir output

Drugs tag on medical devices causing a short supply line: Mfr

Govt notifies Govt Analyst for all classes of drugs as per…


Enter your email address:

Delivered by FeedBurner

Latest updates

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading